201 related articles for article (PubMed ID: 35627184)
1. Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing.
Nkosi D; Casler VL; Syposs CR; Oltvai ZN
Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627184
[TBL] [Abstract][Full Text] [Related]
2. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
3. Rapid clinical mutational testing of
Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
[TBL] [Abstract][Full Text] [Related]
4. Resolving Discrepancies in Idylla
George GV; Liu H; Jajosky AN; Oltvai ZN
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790156
[No Abstract] [Full Text] [Related]
5. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
[TBL] [Abstract][Full Text] [Related]
6. Performance of Idylla
Makutani Y; Sakai K; Yamada M; Wada T; Chikugo T; Satou T; Iwasa Y; Yamamoto H; de Velasco MA; Nishio K; Kawamura J
Int J Clin Oncol; 2022 Jul; 27(7):1180-1187. PubMed ID: 35474548
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Biocartis IDYLLA ™ cartridge assay with Qiagen GeneReader NGS for detection of targetable mutations in EGFR, KRAS/NRAS, and BRAF genes.
Haiduk T; Brockmann M; Tillmann RL; Pieper M; Lüsebrink J; Schildgen V; Schildgen O
Exp Mol Pathol; 2021 Jun; 120():104634. PubMed ID: 33773991
[TBL] [Abstract][Full Text] [Related]
8. Rapid Somatic Mutation Testing in Colorectal Cancer by Use of a Fully Automated System and Single-Use Cartridge: A Comparison with Next-Generation Sequencing.
Al-Turkmani MR; Godwin KN; Peterson JD; Tsongalis GJ
J Appl Lab Med; 2018 Sep; 3(2):178-184. PubMed ID: 33636938
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
Franczak C; Witz A; Geoffroy K; Demange J; Rouyer M; Husson M; Massard V; Gavoille C; Lambert A; Gilson P; Gambier N; Scala-Bertola J; Merlin JL; Harlé A
PLoS One; 2020; 15(1):e0227294. PubMed ID: 31940389
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of
Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer.
Tsongalis GJ; Al Turkmani MR; Suriawinata M; Babcock MJ; Mitchell K; Ding Y; Scicchitano L; Tira A; Buckingham L; Atkinson S; Lax A; Aisner DL; Davies KD; Wood HN; O'Neill SS; Levine EA; Sequeira J; Harada S; DeFrank G; Paluri R; Tan BA; Colabella H; Snead C; Cruz-Correa M; Ramirez V; Rojas A; Huang H; Mackinnon AC; Garcia FU; Cavone SM; Elfahal M; Abel G; Vasef MA; Judd A; Linder MW; Alkhateeb K; Skinner WL; Boccia R; Patel K
Am J Clin Pathol; 2020 Jul; 154(2):266-276. PubMed ID: 32525522
[TBL] [Abstract][Full Text] [Related]
13. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
[TBL] [Abstract][Full Text] [Related]
14. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
15. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla
Michaelidou K; Karniadakis I; Pantelaion V; Koutoulaki C; Boukla E; Folinas K; Dimaras P; Papadaki MA; Koutsopoulos AV; Mavroudis D; Vourlakou C; Mavridis K; Agelaki S
Expert Rev Mol Diagn; 2024; 24(1-2):89-98. PubMed ID: 38193169
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
[TBL] [Abstract][Full Text] [Related]
17. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
Zekri J; Baghdadi MA; Alardati H; Khallaf H; Kabanja JH
Exp Mol Pathol; 2019 Oct; 110():104270. PubMed ID: 31207216
[TBL] [Abstract][Full Text] [Related]
19. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.
Pisapia P; Malapelle U; Roma G; Saddar S; Zheng Q; Pepe F; Bruzzese D; Vigliar E; Bellevicine C; Luthra R; Nikiforov YE; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Bihl M; Savic S; Bubendorf L; de Biase D; Tallini G; Hwang DH; Sholl LM; Vander Borght S; Weynand B; Stieber D; Vielh P; Rappa A; Barberis M; Fassan M; Rugge M; De Andrea CE; Lozano MD; Lupi C; Fontanini G; Schmitt F; Dumur CI; Bisig B; Bongiovanni M; Merkelbach-Bruse S; Büttner R; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2019 May; 127(5):285-296. PubMed ID: 31021538
[TBL] [Abstract][Full Text] [Related]
20. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
